1221714-48-2

Basic information

• Product Name: 4-chloro-2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine
• Synonyms: 4-chloro-2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine
• CAS NO: 1221714-48-2
• Molecular Weight: 358.943
• Mol File: 1221714-48-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-chloro-2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine(1221714-48-2)
• EPA Substance Registry System: 4-chloro-2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine(1221714-48-2)

Safety Data

• Hazardous Substances Data: 1221714-48-2(Hazardous Substances Data)

Upstream product

• 869335-19-3 4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine 
• 98-80-6 phenylboronic acid 
• 100-47-0 benzonitrile 
• 108-99-6 3-Methylpyridine 
• 10586-52-4 2-phenyl-1H-pyrrolo[2,3-b]pyridine 
• 1261726-72-0 4-chloro-2-phenyl-1H-pyrrolo[2,3-b]pyridine 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 55052-28-3 4-chloro-7-azaindole 
• 1221714-47-1 4-chloro-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1221714-50-6 3-fluoro-4-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)-phenylamine 
• 1221714-49-3 3-fluoro-4-[2-phenyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yloxy]-phenyl-carbamic acid t-butyl ester 
• 1221713-88-7 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid [3-fluoro-4-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)-phenyl]-amide 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF ULK1

The present technology is directed to compounds, compositions, and methods related to inhibition of ULK1 and treatment of cancers therefrom.

HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR

Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound.